Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
